# RXFP2

## Overview
RXFP2, or relaxin family peptide receptor 2, is a gene that encodes a G protein-coupled receptor involved in various physiological processes, particularly in reproductive and bone health. The RXFP2 receptor is primarily recognized for its role in mediating the effects of insulin-like peptide 3 (INSL3), a hormone crucial for testicular descent during fetal development. Structurally, RXFP2 features leucine-rich repeat (LRR) modules that facilitate ligand binding, and its activation involves complex interactions with INSL3, characterized by a two-stage binding model. Beyond its reproductive functions, RXFP2 is expressed in osteoblasts, where it influences bone proliferation and differentiation, and in the kidney, where it may regulate glomerular cell proliferation. Mutations in the RXFP2 gene have been linked to clinical conditions such as cryptorchidism and osteoporosis, underscoring its importance in human health (Halls2015International; Scott2012The; Ferlin2008Mutations).

## Structure
RXFP2, a G protein-coupled receptor, features a complex molecular structure essential for its function. The primary structure of RXFP2 consists of a sequence of amino acids forming the protein chain. Its secondary structure includes leucine-rich repeat (LRR) modules, which are crucial for ligand binding, particularly with the peptide hormone INSL3 (Scott2012The). The tertiary structure involves the three-dimensional folding of the protein, allowing the LRR domain to interact with INSL3, forming extensive contacts along the LRR repeats (Scott2012The).

The LRR domain of RXFP2 is modeled on the Nogo receptor structure, highlighting specific amino acids that mediate INSL3 binding, such as Asp 80, Lys 82, and Thr 84 (Scott2012The). Key residues in RXFP2, including Phe 131, Gln 133, Trp 177, and Asp 227, are identified as significantly contributing to binding with INSL3 (Scott2012The). The interaction between RXFP2 and INSL3 involves electrostatic attractions and packing interactions, with Trp B27 of INSL3 forming direct contacts with residues in LRR 1 (Scott2012The).

Post-translational modifications such as glycosylation and phosphorylation may affect RXFP2's function and signaling, although specific details are not provided in the context. The receptor's structure and interactions are crucial for its role in physiological processes.

## Function
RXFP2, or relaxin family peptide receptor 2, is a G protein-coupled receptor primarily involved in reproductive and bone-related functions. It is the cognate receptor for insulin-like peptide 3 (INSL3) and is structurally similar to RXFP1. RXFP2 is expressed in various tissues, including the ovary, testis, and gubernaculum, where it plays a critical role in testicular descent during fetal development by mediating the effects of INSL3 (Halls2015International; van2008Relaxin).

In bone, RXFP2 is expressed in osteoblasts and is involved in bone physiology, regulating genes necessary for bone proliferation and differentiation. Mutations in RXFP2 are linked to reduced bone density and osteoporosis in men (Halls2015International). RXFP2 signaling involves adenylyl cyclase activation and cAMP generation, utilizing a subset of G proteins, including Ga s and Ga oB, to modulate cellular responses (Halls2015International; Halls2007Relaxin).

In the kidney, RXFP2 is expressed in mesangial cells and may regulate glomerular cell proliferation during development. Its expression is influenced by the transcription factor Pod1, which negatively regulates RXFP2 expression in the kidney (Halls2015International). RXFP2's role in the central nervous system is less defined but may influence sensorimotor function (Halls2015International).

## Clinical Significance
Mutations in the RXFP2 gene are associated with several clinical conditions, most notably cryptorchidism and osteoporosis. Cryptorchidism, a condition characterized by the failure of testicular descent, has been linked to recessive variants in the RXFP2 gene. In a study involving a family with four boys affected by bilateral cryptorchidism, a homozygous missense variant in RXFP2 was identified. This variant, Gly499Glu, was found to be non-functional, leading to poor cell surface expression and inability to bind the ligand INSL3, which is crucial for testicular descent (Ayers2019Familial).

In addition to its role in reproductive health, RXFP2 mutations have been implicated in bone metabolism disorders. The T222P mutation in the RXFP2 gene is associated with reduced bone mineral density (BMD) in young men, leading to conditions such as osteopenia and osteoporosis. Studies have shown that 64% of individuals with this mutation exhibit reduced BMD, despite having normal testosterone levels. This suggests that RXFP2 mutations may contribute to osteoporosis through mechanisms involving osteoblast dysfunction rather than hormonal deficiencies (Ferlin2008Mutations). These findings highlight the gene's significance in both reproductive and bone health.

## Interactions
RXFP2, a G protein-coupled receptor, primarily interacts with the peptide hormone INSL3. This interaction is crucial for the receptor's activation and subsequent signaling pathways. The binding of INSL3 to RXFP2 involves specific residues on both the ligand and the receptor. Key residues on INSL3 include His B12, Arg B16, Val B19, and Trp B27, while RXFP2 features critical residues such as Phe 131, Gln 133, Trp 177, Ile 179, Asp 227, Glu 229, Glu 273, and Asp 275 (Scott2012The).

The interaction between INSL3 and RXFP2 is characterized by a two-stage binding model. Initially, INSL3 binds to a high-affinity site within the ectodomain of RXFP2, which facilitates a conformational change allowing interaction with a secondary, lower-affinity site in the transmembrane region. This dual-site interaction is essential for optimal receptor activation and signal transduction (Halls2005Multiple).

RXFP2 also interacts with H2 relaxin, although with different binding dynamics compared to INSL3. H2 relaxin can bind to both RXFP1 and RXFP2, but INSL3 specifically binds and activates RXFP2, highlighting the receptor's ligand specificity (Petrie2015In; Scott2012The).


## References


[1. (Halls2015International) Michelle L. Halls, Ross A. D. Bathgate, Steve W. Sutton, Thomas B. Dschietzig, and Roger J. Summers. International union of basic and clinical pharmacology. xcv. recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1–4, the receptors for relaxin family peptides. Pharmacological Reviews, 67(2):389–440, March 2015. URL: http://dx.doi.org/10.1124/pr.114.009472, doi:10.1124/pr.114.009472. This article has 113 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.114.009472)

[2. (Scott2012The) Daniel J. Scott, K. Johan Rosengren, and Ross A. D. Bathgate. The different ligand-binding modes of relaxin family peptide receptors rxfp1 and rxfp2. Molecular Endocrinology, 26(11):1896–1906, November 2012. URL: http://dx.doi.org/10.1210/me.2012-1188, doi:10.1210/me.2012-1188. This article has 40 citations.](https://doi.org/10.1210/me.2012-1188)

[3. (Halls2005Multiple) Michelle L. Halls, Courtney P. Bond, Satoko Sudo, Jin Kumagai, Tania Ferraro, Sharon Layfield, Ross A. D. Bathgate, and Roger J. Summers. Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (lgr7 and lgr8). Journal of Pharmacology and Experimental Therapeutics, 313(2):677–687, January 2005. URL: http://dx.doi.org/10.1124/jpet.104.080655, doi:10.1124/jpet.104.080655. This article has 98 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/jpet.104.080655)

[4. (Ferlin2008Mutations) Alberto Ferlin, Anastasia Pepe, Lisa Gianesello, Andrea Garolla, Shu Feng, Sandro Giannini, Manuela Zaccolo, Arianna Facciolli, Roy Morello, Alexander I Agoulnik, and Carlo Foresta. Mutations in the insulin-like factor 3 receptor are associated with osteoporosis. Journal of Bone and Mineral Research, 23(5):683–693, May 2008. URL: http://dx.doi.org/10.1359/jbmr.080204, doi:10.1359/jbmr.080204. This article has 116 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1359/jbmr.080204)

[5. (Ayers2019Familial) Katie Ayers, Rakesh Kumar, Gorjana Robevska, Shoni Bruell, Katrina Bell, Muneer A Malik, Ross A Bathgate, and Andrew Sinclair. Familial bilateral cryptorchidism is caused by recessive variants in rxfp2. Journal of Medical Genetics, 56(11):727–733, June 2019. URL: http://dx.doi.org/10.1136/jmedgenet-2019-106203, doi:10.1136/jmedgenet-2019-106203. This article has 20 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2019-106203)

[6. (Halls2007Relaxin) M L Halls, E T van der Westhuizen, R A D Bathgate, and R J Summers. Relaxin family peptide receptors – former orphans reunite with their parent ligands to activate multiple signalling pathways. British Journal of Pharmacology, 150(6):677–691, March 2007. URL: http://dx.doi.org/10.1038/sj.bjp.0707140, doi:10.1038/sj.bjp.0707140. This article has 94 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/sj.bjp.0707140)

[7. (Petrie2015In) Emma J. Petrie, Samantha Lagaida, Ashish Sethi, Ross A. D. Bathgate, and Paul R. Gooley. In a class of their own – rxfp1 and rxfp2 are unique members of the lgr family. Frontiers in Endocrinology, September 2015. URL: http://dx.doi.org/10.3389/fendo.2015.00137, doi:10.3389/fendo.2015.00137. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2015.00137)

[8. (van2008Relaxin) Emma T. van der Westhuizen, Michelle L. Halls, Chrishan S. Samuel, Ross A.D. Bathgate, Elaine N. Unemori, Steven W. Sutton, and Roger J. Summers. Relaxin family peptide receptors – from orphans to therapeutic targets. Drug Discovery Today, 13(15–16):640–651, August 2008. URL: http://dx.doi.org/10.1016/j.drudis.2008.04.002, doi:10.1016/j.drudis.2008.04.002. This article has 51 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.drudis.2008.04.002)